Abstract: The present invention generally relates to an extracellular vesicle (EV) comprising a subunit of a heterodimeric transcription factor, an EV polypeptide, and a monomeric cis-cleaving intein and a method of using the EV.

Abstract: The robot cleaner includes a case, a suction device provided in the case, a suction nozzle for sucking dust from a floor by driving of the suction device, a dust collection device for collecting foreign substances contained in the air sucked via the suction nozzle, a wheel unit to allow movement, a main controller for controlling the driving of the suction device and the wheel unit, a Wi-Fi module provided in the case to provide Access Point (AP), and a NFC module provided in the case to provide an external terminal with AP information for accessing to the AP through NFC communication.

Abstract: The robot cleaner includes a case, a suction device provided in the case, a suction nozzle for sucking dust from a floor by driving of the suction device, a dust collection device for collecting foreign substances contained in the air sucked via the suction nozzle, a wheel unit to allow movement, a main controller for controlling the driving of the suction device and the wheel unit, a Wi-Fi module provided in the case to provide Access Point (AP), and a NFC module provided in the case to provide an external terminal with AP information for accessing to the AP through NFC communication.

Abstract: The robot cleaner includes a case, a suction device provided in the case, a suction nozzle for sucking dust from a floor by driving of the suction device, a dust collection device for collecting foreign substances contained in the air sucked via the suction nozzle, a wheel unit to allow movement, a main controller for controlling the driving of the suction device and the wheel unit, a Wi-Fi module provided in the case to provide Access Point (AP), and a NFC module provided in the case to provide an external terminal with AP information for accessing to the AP through NFC communication.

Abstract: The robot cleaner includes a case, a suction device provided in the case, a suction nozzle for sucking dust from a floor by driving of the suction device, a dust collection device for collecting foreign substances contained in the air sucked via the suction nozzle, a wheel unit to allow movement, a main controller for controlling the driving of the suction device and the wheel unit, a Wi-Fi module provided in the case to provide Access Point (AP), and a NFC module provided in the case to provide an external terminal with AP information for accessing to the AP through NFC communication.

Abstract: The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.

Abstract: The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.

Abstract: The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.